Risk Factors for Severe Hypertension and Proteinuria After Treatment With Vascular Endothelial Growth Factor Signaling Pathway Inhibitors Among Patients With Cancer

Affiliations

• ¹ Division of Nephrology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
• ² Division of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
• ³ Lahey Hospital and Medical Center, Burlington, Massachusetts, USA.
• ⁴ Department of Biostatistics, Harvard TH Chan School of Public Health, Boston, Massachusetts, USA.
• ⁵ Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, USA.
• ⁶ Northwell Health, New Hyde Park, New York, USA.
• ⁷ Division of Kidney Diseases and Hypertension, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, New York, USA.
• ⁸ Division of Nephrology, University Health Network, University of Toronto, Toronto, Ontario, Canada.
• ⁹ Division of Renal Diseases and Hypertension, Department of Internal Medicine, University of Texas Health Science Center at Houston-McGovern Medical School, Texas, USA.
• ¹⁰ Adult Survivorship Program, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.